Pharmaceutical thrombosis prophylaxis, bleeding complications and thromboembolism in a national cohort of hysterectomy for benign disease

BACKGROUND

Pharmaceutical thrombosis prophylaxis (PTP) with low-molecular-weight heparin (LMWH) is highly effective in preventing venous thromboembolic events (VTEs) and fatal pulmonary embolism. Important risk factors for VTEs are surgery and immobilization, along with malignancy. Many studies involving gynaecological malignancies show no increased risk for bleeding complications with PTP. Little is known about the PTP-associated risk for bleeding complications with hysterectomy for benign disease, or about current VTE incidence in the less-invasive hysterectomy methods.

METHODS

Our observational prospective national 1-year cohort from 1 January to 31 December 2006 in 53 hospitals represented 79.4% (5297 of 6645) of hysterectomies performed for benign cause in Finland in 2006. We evaluated PTP use and VTE incidence. Operative and post-operative bleeding complications were analysed with logistic regression adjusted for confounders: age, BMI, experience of the gynaecological surgeon, hospital type, indication for hysterectomy, uterine weight, operative haemorrhage, concomitant surgery, adhesiolysis and antibiotic prophylaxis.

RESULTS

Hysterectomies were performed by three main approaches: 2345 vaginal hysterectomies (VHs, 44%), of which 1433 were for uterine prolapse and 912 for other indications, 1679 laparoscopic hysterectomies (LHs, 32%) and 1255 abdominal hysterectomies (AHs, 24%). PTP was given to 64.8% of patients (3420 of 5279) and was identified as LMWH in 3313 patients (97%); 107 left unidentified. By type of hysterectomy, PTP was given in VH for uterine prolapse to 73.2% of patients, VH for other indication to 51.6%, in LH to 59.4% and in AH to 71.9%. For all hysterectomies analysed together, PTP doubled the odds for post-operative haemorrhage or haematoma. By type of hysterectomy, PTP associated with post-operative haemorrhage or haematoma in VH for prolapse [2.7% of PTP given, versus 0.8% of no PTP; odds ratio (OR): 4.82, 95% confidence interval (CI): 1.38–16.83]; and in AH (3.1% versus 1.4%; OR: 2.87, 95% CI: 1.03–7.98), and in AH also with post-operative transfusion (3.1% versus 1.4%; OR: 3.34, 95% CI: 1.41–7.88). For LH and VH for indications other than prolapse, the effect of PTP on post-operative haemorrhage was non-significant. For VH, the risk for post-operative haemorrhage fell with age. Operative mean haemorrhage with all hysterectomy types, and operative bleeding complications in AH and VH also fell with age. Obesity increased haemorrhage  and operative bleeding complications for LH and VH, whereas post-operative bleeding complications were less for the obese in AH. VTEs were 6 of 5279 (0.1%): two PEs each occurred after AH and VH, and two deep venous thromboses after LH.

CONCLUSIONS

With a relatively wide PTP coverage (64.8%), VTEs were rare (0.1%). All affected had received PTP. Analysis of efficacy, meaning interpretation of how many VTEs or deaths were prevented, cannot be done from our observational study but related to safety in hysterectomy for benign disease, PTP associated with post-operative bleeding complications with AH and with VH for prolapse.

Trial registration number: ClinicalTrials.gov protocol (NCT00744172).

Source:
http://humrep.oxfordjournals.org/rss/current.xml

Uterus transplantation in a non-human primate: long-term follow-up after autologous transplantation

BACKGROUND

Uterus transplantation (UTx) may provide the first available treatment for women affected by uterine infertility. The present study aimed to further develop a surgical technique for autologous UTx in a non-human primate species and to assess long-term function.

METHODS

Female baboons (n= 16) underwent autologous transplantation of the uterus with the Fallopian tubes and ovaries, performed with a previously published surgical technique (n= 6, Group 1) or using a modified technique (n= 10; Group 2). The uterine arteries were dissected to the proximal end of the anterior branch (Group 1) or the entire (Group 2) internal iliac artery, and the ovarian veins were dissected to the crossing over the ureter (Group 1) or further cranially to include greater lengths and patches of the cava/renal vein (Group 2). Back-table preparation created common venous and arterial ends with arterial anastomosis either end-to-side to the left external iliac artery (Group 1) or end-to-end to the left internal iliac artery (Group 2).

RESULTS

Overall short-time survival of the animals was 88% (66% in Group 1 and 100% in Group 2). Of all the operated animals, 75% (66% in Group 1 and 80% in Group 2) resumed ovarian cyclicity. Regular menstruation after UTx was demonstrated only in Group 2 (60%). Menstruating animals (n= 6) were each exposed to timed mating for ≥5 menstrual cycles, but pregnancy did not occur. Adhesions and tubal blockage were seen in post-mortem analysis.

CONCLUSIONS

The modified UTx model of Group 2 is a safe procedure and shows resumed long-term uterine function in a majority of the animals, although pregnancy could not be demonstrated.

Source:
http://humrep.oxfordjournals.org/rss/current.xml

Parental infertility, infertility treatment and hepatoblastoma: a report from the Children’s Oncology Group

BACKGROUND

A recent study suggested a markedly increased risk of hepatoblastoma (HB) among children conceived with treatment for infertility. However, it is not clear whether this finding is confounded by the association between HB and low birthweight (LBW).

METHODS

Associations between parental infertility and its treatment and HB were examined using data from a case–control study conducted through the Children's Oncology Group (COG). Telephone interviews were completed for 383 mothers of cases diagnosed with HB at US COG institutions between January 2000 and December 2008 and for 387 mothers of controls recruited through state birth registries. Logistic regression was used to examine possible associations.

RESULTS

After adjusting for birthweight and other potential confounders, no significant association was found for any of the measures of parental infertility or its treatment. In HB cases conceived through assisted reproductive technology (ART), 4 of 16 also had Beckwith–Wiedemann syndrome (BWS) compared with 9 of 365 in HB cases without ART.

CONCLUSIONS

Little evidence of an association between parental infertility or its treatment and HB was found. The relationship found in a previous study could be due to LBW and BWS which are risk factors for HB and also associated with parental infertility and its treatment.

Source:
http://humrep.oxfordjournals.org/rss/current.xml

Pregnancy outcome in women with endometriomas achieving pregnancy through IVF

BACKGROUND

There is a growing consensus that ovarian endometriomas should not be systematically removed in women selected for IVF. However, some recent evidence suggested that the presence of these cysts may negatively affect the course of pregnancy.

METHODS

We set up a multicenter retrospective cohort study, including two infertility units. We analyzed data from patients achieving singleton clinical pregnancies through IVF comparing the pregnancy outcome between 78 pregnant women with endometriomas at the time of IVF and 156 patients who achieved pregnancy through IVF without endometriomas.

RESULTS

The number of live births in women with and without endometriomas were 61 (78%) and 130 (83%), respectively (P = 0.39). The adjusted odds ratio (OR) of live birth in affected cases was 0.79 [95% confidence interval (CI): 0.38–1.68]. No differences were observed in late pregnancy and neonatal outcomes between the two groups. In particular, the rate of preterm birth and small-for-gestational age (SGA) was similar. The adjusted ORs were 0.47 (95% CI: 0.14–1.54) and 0.56 (95% CI: 0.12–2.56), respectively.

CONCLUSIONS

Women with endometriomas achieving pregnancy through IVF do not seem to be exposed to a significant increased risk of obstetrical complications.

Source:
http://humrep.oxfordjournals.org/rss/current.xml

BDNF Val66Met polymorphism is associated with Stage III-IV endometriosis and poor in vitro fertilization outcome

BACKGROUND

The recently identified human brain-derived neurotrophic factor (BDNF) Val66Met polymorphism was found to be associated with altered susceptibility to some neuropsychiatric disorders. Interestingly, BDNF together with its receptors TrkB and p75 are extensively expressed in female reproduction system. The aim of this study is to investigate whether the BDNF Val66Met polymorphism plays a role in endometriosis, endometriosis-related infertility and the outcomes of IVF and embryo transfer (IVF–ET).

METHODS

A case–control study included 425 endometriosis patients and 244 control Chinese Han women. The genotyping of the BDNF Val66Met polymorphism was performed by the fluorescence resonance energy transfer method. The plasma and follicular fluid concentrations of BDNF on the day of oocyte retrieval were measured by ELISA. The general clinical data from the endometriosis-related and tubal obstructed infertile patients treated with IVF–ET were analyzed.

RESULTS

There was no association between the BDNF Val66Met polymorphism and overall endometriosis (P> 0.05), whereas higher genotype and allele frequencies of the BDNFMet polymorphism were found in the Stage III–IV endometriosis (both P< 0.01) and endometriosis-related infertile patients (both P< 0.05). Moreover, during IVF and embryo transfer (IVF–ET) treatment, fewer mature oocytes (P< 0.05) and lower fertilization rate (P< 0.01) were found in BDNFMet/Met carriers compared with those in BDNFVal/Val carriers with infertility. Follicular-fluid BDNF concentration in BDNFMet/Met carriers was lower compared with that in BDNFVal/Val individuals (P< 0.01).

CONCLUSIONS

Our results suggest that the BDNFMet single-nucleotide polymorphism might contribute to the increased susceptibility to the Stage III–IV endometriosis and endometriosis-related infertility. Moreover, infertile patients with the BDNFMet/Met genotype had a poorer IVF outcome compared with the BDNFVal/Val genotype individuals, which might in part be due to the decreased BDNF levels in follicular fluids after controlled ovarian hyperstimulation.

Source:
http://humrep.oxfordjournals.org/rss/current.xml

Paired-box gene 2 is down-regulated in endometriosis and correlates with low epidermal growth factor receptor expression

BACKGROUND

Paired-box 2 (Pax2) is involved in the development of the female genital tract and has been associated with endometrial pathologies. The expression of Pax2 is induced by epidermal growth factor (EGF) and estrogens. In the present study, Pax2 expression and regulation were investigated in endometriosis.

METHODS AND RESULTS

Pax2 protein expression was assessed by immunohistochemistry in the eutopic (i.e. inside the uterus) and ectopic tissue (endometriosis) from 11 patients. Immunoreactivity was high in the endometrium, with strong epithelial and weaker stromal staining. Similar expression patterns of Pax2 were observed in the endometrium of women without endometriosis (n = 12). The mRNA level of Pax2 was assessed by real-time PCR in the eutopic and ectopic endometria of 14 patients and in the endometrium from women without endometriosis (n = 20). Pax2 expression was lower in endometriotic lesions than that in the eutopic endometrium of patients (P< 0.001) and controls (P= 0.007). Three possible mechanisms determining low Pax2 expression were investigated: EGF signalling, CpG DNA methylation of the Pax2 promoter and steroid response. The mRNA level of the EGF receptor (EGFR1) was assessed in the samples used for Pax2 mRNA assessment. A significant correlation between EGFR1 and Pax2 in both eutopic and ectopic tissues was observed (R = 0.58; slope regression line, 0.81; 95% CI: 0.09–1.52 and R = 0.54; slope regression line, 2.51; 95% CI: 0.02–4.99, respectively). CpG DNA methylation was analyzed by methyl-specific PCR in two regions of the Pax2 promoter but they were unmethylated in all samples. Steroid responsiveness was assessed using endometrial explant cultures and Pax2 was not regulated by either 17β-estradiol or progesterone.

CONCLUSIONS

In endometriosis patients, Pax2 is down-regulated in the lesions compared with the eutopic tissue, possibly due to low EGF signalling.

Source:
http://humrep.oxfordjournals.org/rss/current.xml

Emotional and relational aspects of egg-sharing: egg-share donors’ and recipients’ feelings about each other, each others’ treatment outcome and any resulting children

BACKGROUND

This paper presents finding from a study of the emotional and relational aspects of egg-sharing, exploring egg-share donors' and recipients' thoughts and feelings about each other, about each other's treatment outcome and any resulting children, as well as their attitudes towards disclosure of donor origins and contact between donors and donor offspring in the future. It is the first study of this population since the removal of donor anonymity in 2005.

METHODS

A paper or online questionnaire was completed anonymously by 48 donors and 38 recipients who took part in egg-sharing between 2007 and 2009. Data were obtained on a range of measures—including demographics, family circumstances, motivations and anxieties, feelings about egg-sharing, retrospective assessments and views on regulation—and analysed to facilitate cross-group and within-group comparisons of donors and recipients.

RESULTS

This study found very few differences between donors and recipients, as well as between successful and unsuccessful egg-share participants. Donors and recipients expressed sentiments of goodwill towards one another, and displayed attitudes of openness regarding disclosure decisions and future contact among donors and donor-conceived offspring. While some donors and recipients wanted to know the outcome of their donor's/recipient's treatment, others preferred not to.

CONCLUSIONS

Most significantly, concerns voiced regarding the potential psychological harm to donors, particularly those whose own treatment ends unsuccessfully, were not borne out by the data.

Source:
http://humrep.oxfordjournals.org/rss/current.xml

High pregnancy rate after microsurgical tubal reanastomosis by temporary loose parallel 4-quadrant sutures technique: a long long-term follow-up report on 961 cases

BACKGROUND

Only a limited portion of sterilized women undergo tubal reanastomosis due to high costs, limited availability of qualified practitioners willing to perform the procedure and increasing success rates with IVF. However, IVF has complications and an increased risk of ectopic pregnancy and multiple pregnancies. Recently, the importance of specialized training for tubal anastomosis has been re-emphasized. This study aimed to report the procedure of our microsurgical tubal reanastomosis by a temporary loose parallel 4-quadrant suture technique and its high pregnancy outcome over the last 20 years.

METHODS

This clinical study retrospectively analyzed data on 961 consecutive patients who underwent tubal reversal between March 1988 and August 2007 in a large urban medical center. All surgical operations were performed by microsurgical tubal reanastomosis using a temporary loose parallel 4-quadrant suture technique by a single surgeon. Subsequent pregnancy outcomes were evaluated.

RESULTS

The overall pregnancy rate was 85.1, 82.6 being intrauterine and 2.5% ectopic. The pregnancy rate was significantly reduced in patients over 40 years old (53.9%) compared with patients aged 40 years or less (90.3%) (P < 0.05). Repair done at the interstitial–ampulla site yielded a significantly higher ectopic pregnancy rate (20.0%) compared with other anastomosis sites (0–3.2%) (P < 0.001).

CONCLUSIONS

This study shows that our technique resulted in a high pregnancy rate comparable with the level of natural fertility. The study also reveals that ectopic pregnancy frequently occurs in tubal reanastomosis of the interstitial–ampulla site compared with other sites.

Source:
http://humrep.oxfordjournals.org/rss/current.xml

Study supports urate protection against Parkinson’s disease, hints at novel mechanism

Public release date: 23-May-2012 [ | E-mail | Share ]

Contact: Mike Morrison mdmorrison@partners.org 617-724-6425 Massachusetts General Hospital

Use of the antioxidant urate to protect against the neurodegeneration caused by Parkinson’s disease appears to rely on more than urate’s ability to protect against oxidative damage. In the May issue of the open-access journal PLoS One, researchers from the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND) describe experiments suggesting the involvement of a novel mechanism in urate’s protection of cultured brain cells against Parkinson’s-like damage.

“Our experiments showed, unexpectedly, that urate’s ability to protect neurons requires the presence of neighboring cells called astrocytes,” says Michael Schwarzschild, MD, PhD, of MGH-MIND, the study’s senior author. “The results suggest there may be multiple ways that raising urate could help protect against neurodegeneration in diseases like Parkinson’s and further support the development of treatments designed to elevate urate in the brain.” Schwarzschild and colleagues in the Parkinson’s Study Group currently are conducting a clinical trial investigating one approach to that strategy.

Characterized by tremors, rigidity, difficulty walking and other symptoms, Parkinson’s disease is caused by destruction of brain cells that produce the neurotransmitter dopamine. Several epidemiological studies suggested that healthy people with elevated levels of urate, a normal component of the blood, may have a reduced risk of developing Parkinson’s disease, and investigations by Schwarzschild’s team found that Parkinson’s patients with higher naturally occuring urate levels had slower progression of their symptoms.

The current study was designed to investigate whether both added urate and urate already present within the cells protect cultured dopamine-producing neurons against Parkinson-like degeneration. In addition, since previous studies suggested that urate’s protective effects depended on the presence of astrocytes star-shaped cells of the central nervous system that provide both structural and metabolic support to neurons the MGH-MIND team explored how the presence of astrocytes affects the ability of urate to protect against damage induced by MPP+, a toxic molecule that produces the same kind of neurodegeneration seen in Parkinson’s and is widely used in research studies.

The experiments showed that, while added urate reduced MPP+-induced cell death by about 50 percent in cultured dopamine-producing mouse neurons, urate treatment virtually eliminated neuronal death in cultures containing both neurons and astrocytes. They also showed that reducing intracellular urate levels by induced expression of the enzyme that breaks it down increased neuronal vulnerability to MPP+ toxicity significantly in cultures that included astrocytes but only slightly in neuron-rich cultures. The fact that the presence of astrocytes greatly increases the protection of both externally applied urate and urate produced within cells indicates that the effect depends on more than urate’s ability to directly protect neurons against oxidative stress.

“A valuable next step will be determining whether endogenous urate is protective in live animal models of Parkinson’s disease,” says Schwarzschild. “It also will be important to determine whether we can selectively increase urate levels in brain cells by targeting urate transporter molecules. The approach now in early clinical trials examines whether treatment with the urate precursor inosine, which increases urate levels throughout the body, can slow the progression of the disease. If we could raise urate levels in brain cells without changing them in the rest of the body, we could avoid the risks of of excessive urate, which when accumulated in joints can cause gout.”

###

Schwarzschild is an associate professor of Neurology at Harvard Medical School. Sara Cipriani, MD, of MGH-MIND is the lead and corresponding author of the PLoS One report. The study was supported by grants from the National Institutes of Health, the Department of Defense and the American Parkinson’s Disease Association.

Read this article:
Study supports urate protection against Parkinson's disease, hints at novel mechanism

Source:
http://www.longevitymedicine.tv/feed/

Recovery From Multiple Sclerosis By Growth Factor In Stem Cells

Editor’s Choice Main Category: Multiple Sclerosis Article Date: 24 May 2012 – 14:00 PDT

Current ratings for: ‘Recovery From Multiple Sclerosis By Growth Factor In Stem Cells’

5 (2 votes)

4.5 (2 votes)

Animals that were injected with hepatocyte growth factor were noted to have grown new neural cells and lower levels of inflammation. Most significantly, the researchers noted that the protective envelope of myelin, the myelin sheath, which surrounds the core of a nerve fiber and facilitates the transmission of nerve impulses, re-grew and covered lesions that were caused by MS.

Robert H. Miller, professor of neurosciences at the School of Medicine and vice president for research at Case Western Reserve University declared: “The importance of this work is we think we’ve identified the driver of the recovery.”

MS is caused by damage to the myelin sheath, the protective covering that surrounds nerve cells. The nerve damage is caused by inflammation, which occurs when the body’s own immune cells attacks the nervous systems located in areas of the brain, the optic nerve, and spinal cord. This damage can cause an interruption of the nerve signals, which results in loss of balance and coordination, cognitive ability, as well as in other functions and in time, these intermittent losses may become permanent. In 2009, Caplan and Miller discovered that mice with MS injected with human mesenchymal stem cells recovered from the type of damage that was brought on by MS. A clinical trial is currently underway based on their research, whereby patients with MS are injected with their own stems cells.

During this trial, the team decided to first establish whether the presence of stem cells or other cells induce recovery. They injected a total of 11 animals with MS with the medium, in which mesenchymal stem cells that were taken from bone marrow grew, discovering that all animals displayed a rapid reduction in functional deficits. An analysis demonstrated that unless the injected molecules had a certain size or weight, i.e. between 50 and 100 kiloDaltons, the course of the disease remained unchanged.

Other research, as well as the team’s own studies, suggested that this was likely to be instigated by the hepatocyte growth factor, which is secreted by mesenchymal stem cells.

The team then injected the animals with either 50 or 100 nanograms of the growth factor on alternate days for a 5-day period and observed a decrease in the level of signaling molecules that promote inflammation, whilst the level of signaling molecules that oppose inflammation increased. The researchers noted a growth of neural cells, whilst nerves that were exposed because of MS were rewrapped with myelin. Recovery was marginally better in those mice that received the 100-nanogram injections compared with those receiving the 50-nanogram injections.

Original post:
Recovery From Multiple Sclerosis By Growth Factor In Stem Cells

Source:
http://www.longevitymedicine.tv/feed/

Healthbeat Report: Predicting Parkinson’s

by Sylvia Perez and Christine Tressel

May 24, 2012 (CHICAGO) — Colonoscopies are known for detecting early signs of cancer in the colon. Now Chicago researchers say this common test may help reveal who might be at risk of developing Parkinson’s disease. They have discovered a clue in the gut that could be a game changer for early diagnosis and even treating the disease.

Richard Fiske Bailey says even he had a hard time realizing something was happening with his body. It was the way he was driving his sports car that caught the attention of friends.

“When I went to shift gears I would reach down with my left hand and shift I would shift with my left hand instead of my right hand, I never noticed it. And people would start to say, what is wrong,” Fiske said.

It took a long time but eventually he had a diagnosis: Parkinson’s disease.

“I was formally diagnosed in 2003 by my fifth neurologist,” Fiske said.

A slight tremor in a hand, tense muscles and slow movements are some of the more distinctive signs suggesting Parkinson’s disease. But even these can be confused with other conditions. That means thousands of cases are not diagnosed until a lot of brain cells are gone.

Parkinson’s disease occurs when the nerve cells in the brain that make a chemical called dopamine are slowly destroyed. No one is sure why that happens.

Now researchers are turning to what would seem an unlikely source of a brain disorder: the gut.

“This area of research is really hot right now, and we think it’s really important,” said Dr. Kathleen Shannon, neurologist, Rush University Medical Center

More:
Healthbeat Report: Predicting Parkinson's

Source:
http://www.longevitymedicine.tv/feed/

Multiple sclerosis walk-through

Participants warm up for the walk held in conjunction with World Multiple Sclerosis Day. Pix by Iqmal Haqim Rosman

Padma Panikker says many know little about the rare disease, a situation that the Multiple Sclerosis Society Malaysia hopes to change. Pix by Iqmal Haqim Rosman

IN conjunction with World Multiple Sclerosis Day on May 30, a charity walk was held at Titiwangsa Lake.

Organised by Multiple Sclerosis Society Malaysia and supported by Novartis Corporation (M) Sdn Bhd, the event had the support of 300, who walked around the lake wearing the society’s official T-shirt.

The walk was flagged off by model Amber Chia, who was there to show support to the cause and learn more about the disease.

“I heard that the percentage of Malaysians with the disease is low, and some do not even know they have it.

“I am here to learn more about the disease. I hope that more people will be aware of multiple sclerosis after this,” she said.

Chia said she did not know much about the disease before she was invited to the event, and was surprised by some of the things she had learnt.

“For example, I thought that only old people get it but some of the patients here have got the disease since they were 13,” said Chia.

Multiple Sclerosis Society Malaysia president Padma Panikker said those who were diagnosed with the disease were usually frightened at first and the society acted as a support group for them.

See the original post:
Multiple sclerosis walk-through

Source:
http://www.longevitymedicine.tv/feed/

NZACA Welcomes $7 million Increase for Dementia

NZACA Welcomes $7 million Increase for Dementia

NZACA Press Release 24 May 2012

NZACA welcomes the governments $7 million p.a. increase for dementia care announced today.

The budget announcement of $40 million for dementia is arrived at by adding together, over a four year period, yearly increases along with the additional funding required to cover demand growth.

This represents a 5.8% increase in the daily subsidy rate and taking into inflationary pressures of 1.8% this represents a 4% overall gain for dementia care operators.

The average amount paid for dementia care per day is $149 depending on where you live in New Zealand.

This is another good increase in the dementia rate and means the underfunding of this service has reduced from about 36% to 20% in the last two years based on the independent 2010 Aged Residential Care Review paid for by the Government, the Chief Executive of NZACA, Martin Taylor, said today.

Everyone in the aged-care sector and the health sector understands the demand for dementia care will increase dramatically and that it is one of the hardest services to deliver. As such this increase will be of great assistance to the 150 operators delivering dementia care to 3100 elderly each and every day in New Zealand.

The independent 2010 Aged Residential Care Review also established the rest home care subsidy was 40% underfunded and the hospital rate 17% underfunded. Unfortunately, these underfunding levels have increased over the last two years as inflationary pressures for these services have not been met.

In 2011, about 3100 people were in dementia care, 11,000 in hospital level care and 16,700 in rest home level care.

Follow this link:
NZACA Welcomes $7 million Increase for Dementia

Source:
http://www.longevitymedicine.tv/feed/

Rates Of Dementia In Underdeveloped Countries Are Double Than Previously Reported

Editor’s Choice Main Category: Alzheimer’s / Dementia Article Date: 23 May 2012 – 15:00 PDT

Current ratings for: ‘Rates Of Dementia In Underdeveloped Countries Are Double Than Previously Reported’

In addition, the team found that just like in developed countries, education offers substantial protection against dementia in less developed nations. The study is published Online First in The Lancet.

Lead study author Martin Prince from King’s College London said:

Our findings suggest that early life influences, education and learning to read and write, may be particularly important for reducing the risk of dementia in late life. We need to understand more about cognitive reserve, how to measure it, and how it is stimulated across cultures.

The high incidence of dementia in less developed countries remind us that we are facing a global epidemic, and there needs to be more focus on prevention.”

Using conventional western diagnostic approaches, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria, earlier studies have suggested that the incidence of dementia might be significantly lower in low- and middle-income countries vs. high-income nations.

However, the new 10/66 Dementia Diagnosis approach uses methods developed and validated in 25 low and middle-income countries. The new approach has been demonstrated to provide accurate diagnoses even in individuals with little or no education.

In order to the compare the incidence of dementia, and to determine whether education and literacy, among other factors are protective against the development of dementia, the team applied both the standard DSM-IV criteria and the 10/66 approach to around 12,800 individuals aged 65+, across 9 urban and rural sites in Mexico, Cuba, Peru, Venezuela, the Dominican Republic, and China.

The researchers found that the 10/66 dementia incidence is 1.5 – 2.5 times higher than the standard DSM-IV criteria calculated. In addition, 10/66 dementia incidence was consistently comparable to, or high than, dementia incidence reported by earlier studies.

Continue reading here:
Rates Of Dementia In Underdeveloped Countries Are Double Than Previously Reported

Source:
http://www.longevitymedicine.tv/feed/

Shop staff will be trained to help dementia sufferers

Ministers believe the basic training in dementia awareness is relevant to anyone working in a public environment, such as shops, transport and banks.

Speaking at the event in East London, the Prime Minister urged businesses to join his national fightback against dementia.

Mr Cameron said companies should do more to make people with dementia able to use their services.

He declared that tackling the disease, which is thought to affect 670,000 people in England, was one of his personal priorities.

Dementia is a terrible, heart breaking disease, he said. Tackling it is a personal priority of mine.

Already 20 big organisations like Lloyds Group, Tesco and E.On have signed up to become more dementia-friendly and over the coming months I want to see many more follow suit.

For the sake of millions in our country weve got to keep this spirit of energy and defiance alive.

Were going to keep searching for treatments, keep looking for ways to make life easier for those with this disease and keep taking the fight to dementia.

Mr Cameron urged young volunteers with the National Citizen Service to help sufferers in care homes.

The youngsters aged 16 and 17 are being asked to help dementia patients take part in craft activities and to take them on trips out of care homes.

Continued here:
Shop staff will be trained to help dementia sufferers

Source:
http://www.longevitymedicine.tv/feed/

Dementia app spots early signs of condition

British scientists developed an iPad-based memory test that can spot dementia in its earliest stages, when treatment can be most beneficial.

Researchers from Cambridge University helped to develop the CANTABmobile test, which assesses patients’ short-term memory with a series of challenges in which they have to remember symbols.

Trials show that the computer program accurately distinguishes normal age-related forgetfulness from dementia and other treatable memory problems.

Dr. John O’Loan, who tested the app at his lab in Warrington, northwestern England, said, “Not everyone with memory problems has dementia. There are a small number of medical conditions — vitamin deficiencies or an underactive thyroid — that we check for if patients have problems with their memory.”

Doctors currently use pen-and-paper tests to screen for the condition, with patients asked a series of questions including the date and whether they can spell “world” backwards.

However, the tests can fail to pick up dementia, particularly in patients with higher academic qualifications.

The iPad app is far more sensitive, even picking up mild cognitive impairment, which can be a precursor to dementia.

Michael Hurt, Dementia Care Program Manager for NHS Walsall added, “We might find that we get people through the system more quickly and more effectively because the screening tool is more accurate, and that’s better for GPs, hospital staff, as well as the people receiving the test.”

Click for more from Sky News.

Follow this link:
Dementia app spots early signs of condition

Source:
http://www.longevitymedicine.tv/feed/

Proposal advances for minimum standards in nursing homes, special dementia care units

By Kay Lazar, Globe Staff

A loophole in Massachusetts law that allows nursing homes to advertise specialized Alzheimers and dementia care units, even though their workers may have no training in caring for such residents, is one step closer to being closed.

A proposal that would establish minimum standards for such units was approved by the House of Representatives Wednesday, and is headed for the state Senate.

The bill would require the Massachusetts Department of Public Health, which regulates nursing homes, to establish minimum standards for facilities with dementia care units.

Similar legislation has been proposed for the past seven years without success, supporters said. But this is the first time the measure has made it this far, this early in the year, they said.

This is certainly way overdue, said James Wessler, president and chief executive of the Alzheimers Association of Massachusetts and New Hampshire.

Often nursing home placement is done in time of crisis, and families are then not good shoppers, Wessler said. So the state has an obligation to have a minimal level of guarantees that facilities are providing the level of dementia care that they say they are giving.

Massachusetts is one of a handful of states without such requirements. A 2005 federal report noted that 44 states at that time had requirements governing training, staffing, security, and other areas for facilities that provided specialized dementia care.

The Massachusetts legislation would require all licensed nursing homes to provide dementia-specific training for all direct-care workers, activities directors, and supervisors. Supporters said it was important to mandate dementia training for staff at all licensed facilities because more than half of people in nursing homes suffer from dementia, even if they are not living in specialized dementia care units.

Additionally, the legislation stipulates that there should be activities programs in dementia special care units that provide activities geared to people with dementia.

Go here to see the original:
Proposal advances for minimum standards in nursing homes, special dementia care units

Source:
http://www.longevitymedicine.tv/feed/

Prayer for Mercy: Henderson family seeks a cure for 6-year-old’s unique condition

Leila Navidi

Mercy Doyle, 6, visits with Tina Lindquist, the program director at Brain Balance Achievement Centers in Henderson on Wednesday, May 23, 2012. Doyle has been diagnosed with the rare neurological disorder Opsoclonus MyoclonusSyndrome.

By Conor Shine (contact)

Thursday, May 24, 2012 | 2 a.m.

Six-year-old Mercy Doyle is like a lot of girls her age.

She loves coloring, swimming and The Little Mermaid. She looks up to her big sister and finds her younger brother kind of annoying.

But to doctors in Nevada and around the country, Mercy is a medical mystery, a child with a unique set of symptoms theyve never seen before.

Mercys medical odyssey began seemingly overnight, her parents say, four years ago during a family vacation to the beach in California.

She kept falling in the sand. She couldnt run around. She was shaky. It was weird, said her father, Kevin Doyle, a worship pastor at Green Valley Christian Center.

Her family rushed back home to Henderson, where Mercy was diagnosed with a viral infection that was attacking her brain. After a few months, her condition seemed to be improving. Then her symptoms worsened again.

Continue reading here:
Prayer for Mercy: Henderson family seeks a cure for 6-year-old's unique condition

Source:
http://www.longevitymedicine.tv/feed/

MONROE: Towns went âBlueâ for National Autism Month

MONROE April was recognized across the United States as National Autism Month and served as an opportunity for everyone to educate the public about autism and the issues within the autism community.

Resident Kimberley Toto decided to go bigger this year and promoted more awareness during World Autism Awareness Day April 2, and not only included the schools but made it a community wide event and asked the two local communities to light it up blue.

This marked her third year promoting this campaign through Autism Speaks, where prominent buildings across North America turned their lights blue in honor of World Autism Awareness Day.

The Empire State Building in New York City did the same thing to promote awareness for the condition.

Inspired by this, Ms. Toto used spotlights and blue Christmas lights on her home in April.

Autism spectrum disorder (ASD) and autism are both general terms for a group of complex disorders of brain development. These disorders are characterized, in varying degrees, by difficulties in social interaction, verbal and nonverbal communication and repetitive behaviors, according to the Autism Speaks website, http://www.autismspeaks.org.

When my daughter was diagnosed it was 1 in 150. In the last several years the numbers increased to 1 in 110, Ms. Toto said. Right before the month of April 2012, the Centers for Disease Control came out with new numbers. It is now 1 in 88 kids that are affected with some form of ASD (Autism Spectrum Disorder).

Autism statistics from the U.S. Centers for Disease Control and Prevention (CDC) identify around 1 in 88 American children as on the autism spectruma 10-fold increase in prevalence in 40 years, according to the organization. Careful research shows that this increase is only partly explained by improved diagnosis and awareness.

Studies also show that autism is three to four times more common among boys than girls. An estimated 1 out of 54 boys and 1 in 252 girls are diagnosed with autism in the United States, according to the Autism Speaks website.

By way of comparison, this is more children than are affected by diabetes, AIDS, cancer, cerebral palsy, cystic fibrosis, muscular dystrophy or Down syndrome, combined, according to the organization.

See the original post here:
MONROE: Towns went âBlueâ for National Autism Month

Source:
http://www.longevitymedicine.tv/feed/

Most Children With Autism Diagnosed at 5 or Older

Data Provide Snapshot of Autism Spectrum Disorder and Special Health Care Needs

By Denise Mann WebMD Health News

Reviewed by Louise Chang, MD

May 24, 2012 — New research provides a snapshot of what life is like for school-aged children with autism spectrum disorder in the U.S.

The findings, which appear in the NCHS Data Brief, highlight areas where there is room for improvement, including earlier diagnosis of autism spectrum disorder and access to behavioral therapies and other services. The new study looked at children aged 6 to 17 with special health care needs and autism spectrum disorder in 2011.

More than half of school-aged kids were age 5 or older when they were first diagnosed with autism spectrum disorder, the study showed. Less than 20% were diagnosed by age 2. The American Academy of Pediatrics recommends that pediatricians screen children for autism at 18 months of age.

The CDC estimates that 1 in 88 children in the U.S. has an autism spectrum disorder. This is the umbrella term for a group of developmental disorders that can range from mild to severe and that often affect social and communication skills. Treatment is individualized, and often involves behavioral therapies to address developmental delays along with medication.

Of the children in the study, about 9 of 10 received one or more therapies. Most commonly these included speech or language therapy and/or social skills training. More than half of these kids took at least one psychiatric medication, including stimulants, anti-anxiety drugs, or antidepressants.

“Our data indicate that many children with autism — the majority — are getting some sort of services such as speech or other individual-based interventions,” says researcher Lisa J. Colpe, PhD, MPH, of the National Institute of Mental Health in Bethesda, Md. “That is great news.”

Outside experts say there are still many gaps in the diagnosis and treatment of autism spectrum disorder among school-aged kids in the U.S.

See original here:
Most Children With Autism Diagnosed at 5 or Older

Source:
http://www.longevitymedicine.tv/feed/